

## Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy	C50	00377a	Cyclophosphamide: CDS Methotrexate and 5-Fluorouracil: Hospital
Metastatic breast carcinoma	C50	00377b	

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Adjuvant treatment: Treatment is administered for 6 cycles

Metastatic: Treatment is administered until disease progression or unacceptable toxicity develops

Admin Order	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1 and 8	5-Fluorouracil <sup>a</sup>	600mg/m <sup>2</sup>	IV bolus	N/A	Every 28 days
2	1 and 8	Methotrexate	40mg/m <sup>2</sup>	IV bolus	N/A	Every 28 days
3	1 to 14 inclusive	Cyclophosphamide	100mg/m <sup>2</sup>	PO one hour before food or on an empty stomach	N/A	Every 28 days
Cyclophosphamide is available as 50mg tablets. Tablets should be swallowed whole with a glass of water.						
<sup>a</sup> See dose modifications section for patients with identified partial DPD deficiency						

### ELIGIBILITY:

- Indications as above
- ECOG status 0-2
- Adequate haematological, renal and liver status

### EXCLUSIONS:

- Hypersensitivity to cyclophosphamide, methotrexate, fluorouracil or any of the excipients.
- Pregnancy
- Lactation
- Known complete DPD deficiency

NCCP Regimen: CMF (Oral)	Published: 01/12/2016 Review: 23/09/2025	Version number: 5
Tumour Group: Breast NCCP Regimen Code: 00377	ISMO Contributor: Prof MacconKeane	Page 1 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist

## TESTS:

### Baseline tests:

- FBC, renal and liver profile
- DPD testing prior to first treatment with 5-Fluorouracil using phenotype and/or genotype testing unless patient has been previously tested

### Regular tests:

- FBC, renal and liver prior to each cycle

### Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

## DOSE MODIFICATIONS:

- Consider a reduced starting dose in patients with identified partial DPD deficiency.
  - Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring.
- Any dose modification should be discussed with a Consultant.

## Haematological:

**Table 1: Dose modification of CMF in haematological toxicity**

ANC ( $\times 10^9$ /L)		Platelets ( $\times 10^9$ /L)	Recommended Dose
>1.5	Or	>90	100%
1-1.49		70-89	75%
<1		<70	Delay

NCCP Regimen: CMF (Oral)	Published: 01/12/2016 Review: 23/09/2025	Version number: 5
Tumour Group: Breast NCCP Regimen Code: 00377	ISMO Contributor: Prof MacconKeane	Page 2 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

**Renal and Hepatic Impairment:**

**Table 2: Dose modification of CMF in renal and hepatic impairment**

Drug	Renal Impairment		Hepatic Impairment			
Cyclophosphamide	Cr Cl (ml/min)	Dose	Severe impairment: Clinical Decision			
	>20	100%				
	10-20	75%				
	<10	50%				
Methotrexate	CrCl (ml/min)	Dose	Bilirubin (micromol/L)		AST	Dose
	≥50	100%	<50	And	<180	100%
	20-50	50%	51-85	Or	>180	75%
	<20	Not recommended. If unavoidable consider haemodialysis	>85	Contra indicated		
5-Fluorouracil	Consider dose reduction in severe renal impairment only		Bilirubin (micromol/L)		AST	Dose
			<85		<180	100%
			>85	or	>180	Contra indicated
			Clinical decision. Moderate hepatic impairment; reduce initial dose by 1/3. Severe hepatic impairment, reduce initial dose by 1/2. Increase dose if no toxicity.			

**SUPPORTIVE CARE:**

**EMETOGENIC POTENTIAL:**

5-fluorouracil: Low (Refer to local policy).

Methotrexate: Low (Refer to local policy).

Cyclophosphamide: Moderate to high (Refer to local policy).

**PREMEDICATIONS:**

Not usually required

**OTHER SUPPORTIVE CARE:**

Patients should have an increased fluid intake of 2-3 litres on day 1 and day 8 to prevent haemorrhagic cystitis with cyclophosphamide.

NCCP Regimen: CMF (Oral)	Published: 01/12/2016 Review: 23/09/2025	Version number: 5
Tumour Group: Breast NCCP Regimen Code: 00377	ISMO Contributor: Prof MacconKeane	Page 3 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Pleural effusion or ascites:** Methotrexate should be used with caution in patients with pleural effusion or ascites, as methotrexate may accumulate in third space fluid compartments.
- **Dihydropyrimidine dehydrogenase (DPD) deficiency:** DPD is an enzyme encoded by the DPYD gene which is responsible for the breakdown of fluoropyrimidines. Patients with DPD deficiency are therefore at increased risk of fluoropyrimidine-related toxicity, including for example stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity. Treatment with 5-Fluorouracil, capecitabine or tegafur-containing medicinal products is contraindicated in patients with known complete DPD deficiency. Consider a reduced starting dose in patients with identified partial DPD deficiency. Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring. Therapeutic drug monitoring (TDM) of fluorouracil may improve clinical outcomes in patients receiving continuous 5-fluorouracil infusions.
- **Hand-foot syndrome (HFS),** also known as palmar-plantar erythrodysesthesia (PPE) has been reported as an unusual complication of high dose bolus or protracted continuous therapy for 5-fluorouracil.
- **Myocardial ischaemia and angina:** Cardiotoxicity is a serious complication during treatment with fluorouracil. Patients, especially those with a prior history of cardiac disease or other risk factors, treated with fluorouracil, should be carefully monitored during therapy.

## DRUG INTERACTIONS:

- CYP3A inhibitors decrease the conversion of cyclophosphamide to both its active and inactive metabolites. Patients should also be counselled with regard to consumption of grapefruit juice.
- CYP3A inducers may also increase the conversion of cyclophosphamide to both its active and inactive metabolites.
- NSAIDs may decrease the clearance of methotrexate by decreasing its renal perfusion and tubular secretion thus increasing its toxicity.
- Sulphonamides and penicillins may displace bound methotrexate from plasma protein increasing serum methotrexate levels and its toxicity.
- Concomitant administration of drugs that cause folate deficiency may lead to increased methotrexate toxicity.
- Ciprofloxacin may inhibit renal tubular transport of methotrexate, increasing serum methotrexate levels and its toxicity.
- Probenecid may inhibit renal excretion of methotrexate, increasing serum methotrexate levels and its toxicity.
- Fluorouracil significantly reduces the metabolism of warfarin. INR and signs of bleeding should be monitored regularly and dose of warfarin adjusted as required.
- Concurrent administration of fluorouracil and phenytoin may result in increased serum levels of phenytoin.
- Caution should be taken when using fluorouracil in conjunction with medications which may affect dihydropyrimidine dehydrogenase activity.

NCCP Regimen: CMF (Oral)	Published: 01/12/2016 Review: 23/09/2025	Version number: 5
Tumour Group: Breast NCCP Regimen Code: 00377	ISMO Contributor: Prof Maccon Keane	Page 4 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

- Fluorouracil is contraindicated in combination with brivudin, sorivudin and analogues as these are potent inhibitors of the 5-FU-metabolising enzyme dihydropyrimidine dehydrogenase (DPD).
- Current drug interaction databases should be consulted for more information.

## REFERENCES:

1. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: 20 yr followup. N.Engl.J.Med. 1995;332(14):901906.
2. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005;330(7485):217.
3. HPRA Direct Healthcare Professional Communication. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity. Accessed Aug 2020 Available at: [https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-\(i-v\)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0](https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-(i-v)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0)
4. Krens S D, Lassche, Jansman G F G A, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Onco/2019; 20:e201-08.
5. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V3 2021. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
6. Endoxana Coated Tablets 50mg Summary of Product Characteristics. Accessed Nov 2021. Available at: [https://www.hpra.ie/img/uploaded/swedocuments/Licence\\_PA2299-027-003\\_21122018112109.pdf](https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2299-027-003_21122018112109.pdf)
7. Methotrexate 1g/10ml Summary of Product Characteristics. Accessed Nov 2021. Available at: [https://www.hpra.ie/img/uploaded/swedocuments/Licence\\_PA0822-206-006\\_19052021104201.pdf](https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0822-206-006_19052021104201.pdf)
8. Fluorouracil 25mg/ml Solution for Injection or Infusion Summary of Product Characteristics. Accessed Nov 2021. Available at: [https://www.hpra.ie/img/uploaded/swedocuments/Licence\\_PA0822-223-001\\_08122020085808.pdf](https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0822-223-001_08122020085808.pdf)

Version	Date	Amendment	Approved By
1	1/12/2016		Prof Maccon Keane
2	26/11/2018	Updated to new NCCP template Standardised dosing in renal and hepatic impairment	Prof Maccon Keane
3	27/12/2019	Updated exclusions, dose modifications for hepatic impairment and drug interactions.	Prof Maccon Keane
4	25/8/2020	Reviewed. Updated exclusion criteria, baseline testing, dose modifications and adverse events with respect to DPD deficiency as per DHPC from HPRA June 2020 Updated Adverse events regarding palmar-plantar erythrodysesthesia	Prof Maccon Keane

NCCP Regimen: CMF (Oral)	Published: 01/12/2016 Review: 23/09/2025	Version number: 5
Tumour Group: Breast NCCP Regimen Code: 00377	ISMO Contributor: Prof Maccon Keane	Page 5 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

5	03/11/2021	Amended renal impairment table. Updated emetogenic potential.	Prof Maccon Keane
---	------------	--	-------------------

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

NCCP Regimen: CMF (Oral)	Published: 01/12/2016 Review: 23/09/2025	Version number: 5
Tumour Group: Breast NCCP Regimen Code: 00377	ISMO Contributor: Prof Maccon Keane	Page 6 of 6
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		